Abeona Therapeutics Announces Licensing of the AIM(TM) Next Generation AAV Gene Therapy Vector Platform From The University of North Carolina at Chapel Hill
September 21, 2016 07:03 ET
|
Abeona Therapeutics Inc.
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - September 21, 2016) - AIM™ vector system is a novel AAV-based vector technology platform that may target CNS and other tissues with increased efficiency...
Abeona Therapeutics to Present at 2016 Aegis Growth Conference
September 16, 2016 17:28 ET
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 16, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing gene and plasma-based...
Abeona Therapeutics Announces Publication of Preclinical Data Supporting Clinical Translation of MPS IIIA Gene Therapy
September 15, 2016 07:03 ET
|
Abeona Therapeutics Inc.
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - September 15, 2016) - Preclinical efficacy data demonstrated significant benefits leading to restoration of SGSH activity and reduction of...
Abeona Therapeutics Enrolls 5th Patient in Phase 1/2 Gene Therapy Clinical Trial for Epidermolysis Bullosa
September 08, 2016 07:03 ET
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 08, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO)EB-101 (gene-corrected skin grafts) has demonstrated promising clinical efficacy in...
Abeona Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
September 07, 2016 07:03 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 07, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing gene and plasma-based...
Abeona Therapeutics to Present at Landmark Angels 6th Annual Investing for Cures 2016 Conference
September 01, 2016 07:03 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 01, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing gene and plasma-based...
Abeona Therapeutics Completes Enrollment of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients
August 29, 2016 07:03 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - August 29, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO): Low-dose cohort (n=3) enrollment completed for ongoing study to evaluate ABO-102 (AAV-SGSH),...
Abeona Therapeutics Announces Second Quarter 2016 Financial Results and Recent Clinical Highlights
August 16, 2016 07:03 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - August 16, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on delivering gene and plasma-based...
Abeona Therapeutics, EB Research Partnership and EB Medical Research Foundation to Collaborate on Epidermolysis Bullosa (EB) Treatments
August 09, 2016 07:03 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - August 09, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) Collaboration will focus on gene therapy treatments for epidermolysis bullosa (EB) EB-101, an...
Abeona Therapeutics anuncia la aprobación regulatoria europea para el estudio clínico de genoterapias en fase 1/2 para pacientes con síndrome de Sanfilippo tipo A (mucopolisacaridosis tipo IIIA, MPS IIIA)
August 04, 2016 07:03 ET
|
Abeona Therapeutics
NUEVA YORK, NY y CLEVELAND, OH--(Marketwired - 4 de agosto de 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO)La aprobación del estudio clínico para ABO-102 (AAV-SGSH) en la Unión Europea representa...